Medigene broadens alliance on T-cell receptors with Bluebird Bio [Reuters]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Reuters
Medigene broadens alliance on T-cell receptors with Bluebird Bio | Reuters Reuters Staff 1 Min Read FRANKFURT (Reuters) - German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion. The number of projects in the alliance, which has Medigene contributing screening tools to identify promising T-cell receptors (TCR), will rise from four to six, Medigene said in a statement on Monday. “If successfully developed and marketed through several indications and markets, Medigene could receive up to $250 million in milestone payments per TCR program in addition to tiered royalty payments on net sales up to a double-digit percentage,” Medigene said. Medigene agreed its alliance with Bluebird in September 2016. Reporting by Ludwig Burger; editing by John Stonestreet All quotes delayed a minimum of 15 minutes. See here for a com
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- Levi & Korsinsky Reminds bluebird bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUEAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)GlobeNewswire
- Investors who lost money on bluebird bio, Inc.(BLUE) should contact Levi & Korsinsky about pending Class Action - BLUEAccesswire
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUEAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form SC
- 3/26/24 - Form 8-K
- BLUE's page on the SEC website